drugset / Trial / NCT04316364
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable Stage II, IIIA, or selected IIIB non-small cell lung cancer (NSCLC) followed by adjuvant SHR-1316 or placebo and monitoring.
Timeline
- Start
- 2020-07-14
- Primary completion
- 2023-04-15
- Completion
- 2026-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |